American Society of Hematology

Figure 1.

$Figure 1. Identification of the malignant population. (A) Gating strategy of nonmalignant CD3+CD4+CD7+CD26+ cells from 10 patients with SS (SS2-SS11). (B) TCRVβ distribution within the CD4+ non-CD26+CD7+ (malignant), CD4+CD26+CD7+ (nonmalignant), and CD8+ T cell populations. Because of incomplete antibody coverage by the TCRVβ screening kit, not all T cells can be assigned to a TCRVβ and are included in the “unmarked” fraction. (C) Assessment of the fraction of CD26+CD7+ cells within the CD4+ population expressing the dominant TCRVβ clone detected in 5 of the 10 patients with SS.$

Identification of the malignant population. (A) Gating strategy of nonmalignant CD3⁺CD4⁺CD7⁺CD26⁺ cells from 10 patients with SS (SS2-SS11). (B) TCRVβ distribution within the CD4⁺ non-CD26⁺CD7⁺ (malignant), CD4⁺CD26⁺CD7⁺ (nonmalignant), and CD8⁺ T cell populations. Because of incomplete antibody coverage by the TCRVβ screening kit, not all T cells can be assigned to a TCRVβ and are included in the “unmarked” fraction. (C) Assessment of the fraction of CD26⁺CD7⁺ cells within the CD4⁺ population expressing the dominant TCRVβ clone detected in 5 of the 10 patients with SS.

This Feature Is Available To Subscribers Only